MapLight Therapeutics Inc. will raise $258.9 million in an IPO and private placement, the first company to go public since the US government shutdown. With a market value of $704.3 million, the Redwood City-based biotech firm is developing treatments for neurological disorders like schizophrenia and Alzheimer’s disease psychosis. Sergey Brin-founded nonprofit Catalyst4’s ownership of shares is expected to decrease following the IPO.

Read more at Yahoo Finance: Novo-Backed MapLight Raises $258.9 Million in US IPO, Placement